New Two-Step transplant shows promise for tough blood cancers
NCT ID NCT01760655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cancer. The goal was to improve cancer-free survival, but patients may need long-term follow-up and medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a hormone mimic curb the need for bloodletting in a blood cancer?
- Can trained immune cells stop blood cancer relapse?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Dual-Action pill tame bone marrow tumors?